Resverlogix Corp.

2013/8/30 10:00


AsiaNet 54087

共同JBN 0981 (2013.8.29)

【カルガリー(カナダ・アルバータ州)2013年8月29日】Resverlogix Corp.(TSX:RVX)は29日、企業広報電話会見とウェブキャストQ&Aセッションを山岳部夏時間(MDT)9月3日午前11時に開催する、と最新更改情報を発表した。





カナダと米国の無料通話番号: 1-800-319-4610

カナダと米国以外からはダイヤル: +1-604-638-5340   




Resverlogix Corp(TSX:RVX)は臨床段階心臓血管病薬会社で、ApoA-I製造関連の化合物を開発している。RVX-208はアテローム性動脈硬化治療用のクラス初の小分子薬であり糖尿病やアルツハイマー病にも効能がある可能性がある。RVX-208は臨床試験段階にある初めてのBETブロモドメイン阻害剤である。Resverlogixの普通株はトロント証券取引所で取引されている(TSX:RVX)。詳しい情報はwww.resverlogix.comへ。ブログはhttp://www.resverlogix.com/blog



Donald J. McCaffrey

President and CEO

Resverlogix Corp.

Phone: 403-254-9252

Email: don@resverlogix.com

Kenneth Lebioda

SVP Business & Corporate Development

Resverlogix Corp.

Phone: 403-254-9252

Email: ken@resverlogix.com

ソース:Resverlogix Corp.

Resverlogix Announces a Corporate Update Conference Call & Webcast


CALGARY, Alberta, Aug. 29, 2013 /PRN=KYODO JBN/ --

- TSX Exchange Symbol: RVX

Resverlogix Corp. (TSX:RVX) today announced they will be hosting a corporate

update conference call and webcast with Q&A on September 3rd at 11 am MDT.

Details for the conference call and webcast are as follows:

Link to webcast: http://services.choruscall.ca/links/resverlogix130905.html

Dial in numbers:

Canada & USA Toll Free Dial In: 1-800-319-4610

Outside of Canada & USA call: +1-604-638-5340   

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET bromodomains.

RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol

transport (RCT), the natural process through which atherosclerotic plaque is

transported out of the arteries and removed from the body by the liver. RVX-208

increases production of Apolipoprotein A-I (ApoA-I), the key building block of

functional high-density lipoprotein (HDL) particles and the type required for

RCT. These newly produced, functional HDL particles are flat and empty and can

efficiently remove plaque and stabilize or reverse atherosclerotic disease.

ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes


About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company

developing compounds involving ApoA-I production. RVX-208 is a first-in-class

small molecule in development for the treatment of diseases such as

atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the

first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares

trade on the Toronto Stock Exchange (TSX: RVX). For further information please

visit www.resverlogix.com. We can be followed on our blog at


This news release may contain certain forward-looking information as defined

under applicable Canadian securities legislation, that are not based on

historical fact, including without limitation statements containing the words

"believes", "anticipates", "plans", "intends", "will", "should", "expects",

"continue", "estimate", "forecasts" and other similar expressions. In

particular, this news release includes forward looking information relating to

research and development activities and the potential role of RVX-208 in the

treatment of diseases such as atherosclerosis, Diabetes Mellitus and

Alzheimer's disease. Our actual results, events or developments could be

materially different from those expressed or implied by these forward-looking

statements. We can give no assurance that any of the events or expectations

will occur or be realized. By their nature, forward-looking statements are

subject to numerous assumptions and risk factors including those discussed in

our Annual Information Form and most recent MD&A which are incorporated herein

by reference and are available through SEDAR at www.sedar.com. The

forward-looking statements contained in this news release are expressly

qualified by this cautionary statement and are made as of the date hereof. The

Company disclaims any intention and has no obligation or responsibility, except

as required by law, to update or revise any forward-looking statements, whether

as a result of new information, future events or otherwise.

Company Contacts:

Donald J. McCaffrey        

President and CEO           

Resverlogix Corp.           

Phone: 403-254-9252        

Email: don@resverlogix.com  

Kenneth Lebioda

SVP Business & Corporate Development

Resverlogix Corp.

Phone: 403-254-9252

Email: ken@resverlogix.com


SOURCE: Resverlogix Corp.